REC-2282 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
34神経線維腫症1

34. 神経線維腫症


臨床試験数 : 137 薬物数 : 213 - (DrugBank : 76) / 標的遺伝子数 : 87 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05130866
(ClinicalTrials.gov)
December 1, 202110/11/2021Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasA Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated MeningiomasNeurofibromatosis Type 2Drug: REC-2282;Drug: PlaceboRecursion Pharmaceuticals Inc.NULLNot yet recruiting12 YearsN/AAll89Phase 2/Phase 3NULL